This study, called SWAP-9, is looking at different ways to manage antiplatelet medicines after you've had a stent placed for coronary artery disease (CAD). Specifically, it's comparing two approaches: continuing with strong antiplatelet medicines like prasugrel or ticagrelor, or switching to a combination of aspirin and clopidogrel. The goal is to see how these different strategies affect your body's antiplatelet response. You might be able to join if you've had a stent and are currently taking aspirin along with prasugrel or ticagrelor. The study will measure how well your blood platelets are being controlled after about 30 days.

Study design

This interventional study plans to enroll 90 participants. It compares two different antiplatelet treatment strategies.

What's involved

Not specified in the trial record.

Compensation

Not stated in the trial record.

Follow-up

Your platelet response will be measured at 30 ± 5 days after starting the new treatment strategy.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.